GLP-1 agonists, such as Ozempic, are blockbuster weight loss and type 2 diabetes drugs that offer a wide range of benefits, including controlling blood sugar, significant weight loss, and potentially preventing heart attacks and strokes. Recent research suggests these drugs may also slow kidney disease progression, relieve sleep apnea, and possibly treat Parkinson’s and Alzheimer’s diseases. Studies show GLP-1s may reduce the risk of many obesity-related cancers, but more research is needed to determine the full extent of their cancer prevention potential. Despite the promising findings, experts caution that the data has limitations and the drugs are not without risks. The high cost and limited insurance coverage for GLP-1s also pose challenges for widespread prescribing.
Source link
Can Popular Weight Loss Drugs Lower Cancer Risk?
